AIMP1 and glioma: We investigated OS in patients following antiangiogenic treatments within AIMP1/2/3-high and -low expression sub-groups (Fig. 4) and the median survival in each group is reported for publicly available glioma datasets and the two clinical trial datasets in Supplementary Table S6.